MedTrace Logo

Effects of Selected Statins on Blood Glucose Levels in Healthy Volunteers

NCT07378293 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-01-30

No results posted yet for this study

Summary

This Phase I randomized clinical trial aims to investigate the short-term effects of three commonly prescribed statins (atorvastatin, rosuvastatin, and simvastatin) at different dose levels on blood glucose homeostasis in healthy volunteers. The study will assess changes in fasting blood glucose, insulin, and C-peptide levels following two days of statin administration under controlled conditions. The research seeks to provide comparative data on the potential diabetogenic effects of these medications.

Conditions

  • Diabete Mellitus
  • Lipid Profile

Interventions

DRUG

Simvastatin (10mg, 20mg, 40mg)

The Simvastatin (10mg, 20mg, 40mg) group participants will be given the drug orally OD for two days

DRUG

Rosuvastatin (5mg, 20mg, 40mg)

The Rosuvastatin (5mg, 20mg, 40mg) group participants will be given the drug orally OD for two days

DRUG

Atorvastatin (10mg, 20mg, 40mg)

The Atorvastatin (10mg, 20mg, 40mg) group participants will be given the drug orally OD for two days

Sponsors & Collaborators

  • Khyber Medical University Peshawar

    collaborator OTHER

  • Shaheed Benazir Bhutto University Sheringal Dir Upper

    lead OTHER

Principal Investigators

  • Dr Abid Ullah, PhD · Shaheed Benazir Bhutto University,sheringal

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-01
Primary Completion
2026-12-30
Completion
2027-02-20

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07378293 on ClinicalTrials.gov